Chemical formula: C₄₆H₅₈N₄O₉ Molecular mass: 810.974 g/mol PubChem compound: 13342
Vinblastine appears to bind to or crystallise critical microtubular proteins of the mitotic spindle, thus preventing their proper polymerisation and causing metaphase arrest. In high concentrations, vinblastine also exerts complex effects on nucleic acid and protein synthesis.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L01CA01 | Vinblastine | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01C Plant alkaloids and other natural products → L01CA Vinca alkaloids and analogues |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| VINBLASTINE SULFATE Solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Vinblastine is an active ingredient of these brands:
Austria (AT)
Brazil (BR)
Cyprus (CY)
Finland (FI)
France (FR)
Hong Kong (HK)
Israel (IL)
Japan (JP)
Singapore (SG)
South Africa (ZA)
Turkey (TR)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
